+86 137 2013 4139
+86 137 2013 4139
| CAS: | 935283-04-8 | Cat No: | JKN00764 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Product Description
| CAS | 935283-04-8 | Cat No | JKN00764 | |
| Name | Linzagolix | |||
| Synonyms | Linzagolix | |||
| Smiles | COC1=C(C(=C(C=C1)F)F)COC2=C(C=C(C(=C2)N3C(=O)C4=C(SC=C4NC3=O)C(=O)O)F)OC | |||
| Chemical Name | 3-[5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl]-2,4-dioxo-1H-thieno[3,4-d]pyrimidine-5-carboxylic acid | |||
| Formula | C22H15F3N2O7S | MWt | 508.4 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix]. Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency, and reproductive dysfunction. As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by preventing intramyometrial growths in the endometrial glands. Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
